Nocardiosis is an infectious disease of global importance, particularly for the immunocompromised population. As a company, we are actively working in nocardiosis by offering a complete package of vaccine readiness and therapy development services.
Introduction to Nocardiosis
Nocardiosis can be classified into two broad categories namely lung specific nocardiosis and systemic nocardiosis which is caused due to the bacteria genera Nocardia. The use of efficient vaccines and therapies is required owing to the extensive mortality rates associated with nocardiosis.
Nocardiosis is due to Nocardia species which encompass Gram positive bacteria that primarily reside within soil and other forms of environmental materials. Through direct inoculation or through the process of breathing, these bacteria are capable to cross over to the human body where they show a range of reactions. Individuals who are immunocompromised such as organ transplantation patients, those with HIV or even cancer have higher chances to get Nocardiosis.
Fig.1 Microbiological diagnostic analysis of nocardiosis.Fig.1 Microbiological diagnosis of nocardiosis. (Lafont E., et al., 2020)
Vaccine Development for Nocardiosis
Reverse Vaccinology
The concurrent development in reverse vaccinology and immunoinformatic has come up with a novel paradigm shift in vaccine research. Applications of whole genome sequencing on Nocardia species suggest which antigens could be utilized for making a multi-epitope vaccine. This procedure does enable to have a thorough characterization of all the protein antigens on the pathogen, thus increasing the chances of recognition of suitable vaccine candidates.
Multi-epitope Vaccine
The design of a multi-epitope vaccine involves the identification of relevant amino acid sequences known as epitopes from virulence proteins or resistance-associated proteins of the pathogen to be used as ingredients. A combination of these epitopes and suitable adjuvants and linkers are used in the formulation of the vaccine. This formulation goes through a series of stringent tests for immunogenicity, safety and efficacy by way of a molecular docking, molecular dynamics simulation and immune simulation.
Therapeutics Development for Nocardiosis
Trimethoprim-Sulfamethoxazole (TMP-SMX) is the central drug in the treatment of infections but has suffered from relatively low prescribers in the treatment of severe multi– drug resistant infections. Despite its effectiveness, there are options that are still being researched as a result of growing antibiotic resistance.
With the universal susceptibility to Nocardia, Linezolid is one such candidate that can be considered as an alternative to TMP-SMX. Other than Linezolid, Imipenem would also be worth considering as it's being studied in the context of the therapy for nocardiosis. As a company, we offer innovative drug and therapy solutions for those suffering from nocardiosis. To learn more about us, click the link below.
Our Services
We do specialize in nocardiosis vaccine and therapy development services in the fight against nocardiosis. Our specialization is to improve the innovative tools for this purpose. We advance through years of research and vast experience in formulation industry as well as by utilization of our cutting edge tools.
- Acute Lethality Models: intraperitoneal (ip) injection of a high dose
- Chronic Infection Models: Swiss white mice and BALB/c mice
- Customized Animal Model Development
Furthermore, our company has the capacity to meet nocardiosis related development projects by exporting comprehensive preclinical services. Alongside our vaccine and therapy development skills, kindly reach out to us if you are interested in our services.
References
- Lafont Emmanuel, et al. "Invasive nocardiosis: disease presentation, diagnosis and treatment–old questions, new answers?." Infection and drug resistance (2020): 4601-4613.
- Zhu, Fei, et al. "Design of a multi-epitope vaccine against six Nocardia species based on reverse vaccinology combined with immunoinformatics." Frontiers in Immunology 14 (2023): 1100188.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
